Probiotic formula reduced colic symptoms in recent study


A recent study1 found that supplementation with the probiotic formula from AB-Biotics (Barcelona, ​​Spain) called AB-Kolicare significantly improved symptoms of colic in infants. In the randomized, double-blind, placebo-controlled study, 112 exclusively breast-fed and breast-fed infants under two months were given either a placebo or the probiotic formula daily for 21 days. AB-Kolicare is composed of a mixture of Bifidobacterium longum CECT7894 (KABP042) and Pediococcus pentosaceus CECT8330 (KABP041) at 1 × 109 colony forming units. The results showed that, compared to placebo, infants taking the probiotic formula had a significantly shorter time to cry on days seven (38 minutes / day vs. 62 minutes / day), 14 (20 minutes / day vs. 50 minutes / day). day) and 21 (14 minutes / day versus 40 minutes / day), as well as an improvement in stool consistency on day 21.

“Colic can be an extremely distressing experience, both for babies and their families,” Jordi Riera, director of business development for AB-Biotics, said in a press release. “Emerging research shows that babies with infantile colic have a different microbiota composition than those without. For example, the presence of Bifidobacterium – beneficial bacteria that digest dietary fiber, help prevent infections and produce vitamins – is only 0.3% in colicky babies, compared to 10% in non-colic infants. This suggests that the gut microbiota may play an important role in disease development and explains why probiotics are being explored as a potential treatment due to their gut strengthening properties. In this study, the probiotic solution contained a strain of B. longum, which is a human resident bifidobacterium (HRB) and one of the most common bifidobacteria in healthy infants. This is important since most other probiotic solutions for infants contain non-HRB substances such as like B. animalis. “

Reference

  1. Chen K et al. “Infant colic treated with Bifidobacterium longum CECT7894 and Pediococcus pentosaceusCECT8330: a randomized, double-blind, placebo-controlled trial. ” Frontiers in pediatrics, Published online ahead of print on September 10, 2021


Source link

Previous Global Amino Acid Metabolism Disorders Treatment Market 2021 Key Player Trends and Analysis 2027 - GlaxoSmithKline, Pfizer, AMINO, Merck
Next What is collagen and do you need collagen supplements?

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *